209 related articles for article (PubMed ID: 32293671)
1. Novel congenital disorder of O-linked glycosylation caused by GALNT2 loss of function.
Zilmer M; Edmondson AC; Khetarpal SA; Alesi V; Zaki MS; Rostasy K; Madsen CG; Lepri FR; Sinibaldi L; Cusmai R; Novelli A; Issa MY; Fenger CD; Abou Jamra R; Reutter H; Briuglia S; Agolini E; Hansen L; Petäjä-Repo UE; Hintze J; Raymond KM; Liedtke K; Stanley V; Musaev D; Gleeson JG; Vitali C; O'Brien WT; Gardella E; Rubboli G; Rader DJ; Schjoldager KT; Møller RS
Brain; 2020 Apr; 143(4):1114-1126. PubMed ID: 32293671
[TBL] [Abstract][Full Text] [Related]
2. Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in man.
Holleboom AG; Karlsson H; Lin RS; Beres TM; Sierts JA; Herman DS; Stroes ES; Aerts JM; Kastelein JJ; Motazacker MM; Dallinga-Thie GM; Levels JH; Zwinderman AH; Seidman JG; Seidman CE; Ljunggren S; Lefeber DJ; Morava E; Wevers RA; Fritz TA; Tabak LA; Lindahl M; Hovingh GK; Kuivenhoven JA
Cell Metab; 2011 Dec; 14(6):811-8. PubMed ID: 22152306
[TBL] [Abstract][Full Text] [Related]
3. A novel role for GalNAc-T2 dependent glycosylation in energy homeostasis.
Verzijl CRC; Oldoni F; Loaiza N; Wolters JC; Rimbert A; Tian E; Yang W; Struik D; Smit M; Kloosterhuis NJ; Fernandez AJ; Samara NL; Ten Hagen KG; Dalal K; Chernish A; McCluggage P; Tabak LA; Jonker JW; Kuivenhoven JA
Mol Metab; 2022 Jun; 60():101472. PubMed ID: 35304331
[TBL] [Abstract][Full Text] [Related]
4. Role of let-7b in the regulation of N-acetylgalactosaminyltransferase 2 in IgA nephropathy.
Serino G; Sallustio F; Curci C; Cox SN; Pesce F; De Palma G; Schena FP
Nephrol Dial Transplant; 2015 Jul; 30(7):1132-9. PubMed ID: 25744272
[TBL] [Abstract][Full Text] [Related]
5. Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor.
Wu YM; Liu CH; Hu RH; Huang MJ; Lee JJ; Chen CH; Huang J; Lai HS; Lee PH; Hsu WM; Huang HC; Huang MC
Cancer Res; 2011 Dec; 71(23):7270-9. PubMed ID: 21990321
[TBL] [Abstract][Full Text] [Related]
6. Mucin glycosylating enzyme GALNT2 suppresses malignancy in gastric adenocarcinoma by reducing MET phosphorylation.
Liu SY; Shun CT; Hung KY; Juan HF; Hsu CL; Huang MC; Lai IR
Oncotarget; 2016 Mar; 7(10):11251-62. PubMed ID: 26848976
[TBL] [Abstract][Full Text] [Related]
7. Loss of Function of GALNT2 Lowers High-Density Lipoproteins in Humans, Nonhuman Primates, and Rodents.
Khetarpal SA; Schjoldager KT; Christoffersen C; Raghavan A; Edmondson AC; Reutter HM; Ahmed B; Ouazzani R; Peloso GM; Vitali C; Zhao W; Somasundara AV; Millar JS; Park Y; Fernando G; Livanov V; Choi S; Noé E; Patel P; Ho SP; ; Kirchgessner TG; Wandall HH; Hansen L; Bennett EP; Vakhrushev SY; Saleheen D; Kathiresan S; Brown CD; Abou Jamra R; LeGuern E; Clausen H; Rader DJ
Cell Metab; 2016 Aug; 24(2):234-45. PubMed ID: 27508872
[TBL] [Abstract][Full Text] [Related]
8. Association of the GALNT2 gene polymorphisms and several environmental factors with serum lipid levels in the Mulao and Han populations.
Li Q; Yin RX; Yan TT; Miao L; Cao XL; Hu XJ; Aung LH; Wu DF; Wu JZ; Lin WX
Lipids Health Dis; 2011 Sep; 10():160. PubMed ID: 21933382
[TBL] [Abstract][Full Text] [Related]
9. GALNT2 suppresses malignant phenotypes through IGF-1 receptor and predicts favorable prognosis in neuroblastoma.
Ho WL; Chou CH; Jeng YM; Lu MY; Yang YL; Jou ST; Lin DT; Chang HH; Lin KH; Hsu WM; Huang MC
Oncotarget; 2014 Dec; 5(23):12247-59. PubMed ID: 25362349
[TBL] [Abstract][Full Text] [Related]
10. Site-specific protein O-glycosylation modulates proprotein processing - deciphering specific functions of the large polypeptide GalNAc-transferase gene family.
Schjoldager KT; Clausen H
Biochim Biophys Acta; 2012 Dec; 1820(12):2079-94. PubMed ID: 23022508
[TBL] [Abstract][Full Text] [Related]
11. GALNT2 regulates ANGPTL3 cleavage in cells and in vivo of mice.
Li X; Zhang Y; Zhang M; Wang Y
Sci Rep; 2020 Sep; 10(1):16168. PubMed ID: 32999434
[TBL] [Abstract][Full Text] [Related]
12. Clinical, neuroradiological, and biochemical features of SLC35A2-CDG patients.
Vals MA; Ashikov A; Ilves P; Loorits D; Zeng Q; Barone R; Huijben K; Sykut-Cegielska J; Diogo L; Elias AF; Greenwood RS; Grunewald S; van Hasselt PM; van de Kamp JM; Mancini G; Okninska A; Pajusalu S; Rudd PM; Rustad CF; Salvarinova R; de Vries BBA; Wolf NI; ; Ng BG; Freeze HH; Lefeber DJ; Õunap K
J Inherit Metab Dis; 2019 May; 42(3):553-564. PubMed ID: 30746764
[TBL] [Abstract][Full Text] [Related]
13. MALDI-MS profiling of serum O-glycosylation and N-glycosylation in COG5-CDG.
Palmigiano A; Bua RO; Barone R; Rymen D; Régal L; Deconinck N; Dionisi-Vici C; Fung CW; Garozzo D; Jaeken J; Sturiale L
J Mass Spectrom; 2017 Jun; 52(6):372-377. PubMed ID: 28444691
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein-CIII
Naber A; Demus D; Slieker R; Nicolardi S; Beulens JWJ; Elders PJM; Lieverse AG; Sijbrands EJG; 't Hart LM; Wuhrer M; van Hoek M
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834292
[TBL] [Abstract][Full Text] [Related]
15. GALNT2 enhances migration and invasion of oral squamous cell carcinoma by regulating EGFR glycosylation and activity.
Lin MC; Huang MJ; Liu CH; Yang TL; Huang MC
Oral Oncol; 2014 May; 50(5):478-84. PubMed ID: 24582885
[TBL] [Abstract][Full Text] [Related]
16. Role of GALNT2 on Insulin Sensitivity, Lipid Metabolism and Fat Homeostasis.
Antonucci A; Marucci A; Trischitta V; Di Paola R
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055114
[TBL] [Abstract][Full Text] [Related]
17. Unique clinical presentations and follow-up outcomes from experience with congenital disorders of glycosylation: PMM2-PGM1-DPAGT1-MPI-POMT2-B3GALNT2-DPM1-SRD5A3-CDG.
Yoldas Celik M; Yazici H; Erdem F; Yuksel Yanbolu A; Aykut A; Durmaz A; Zeybek S; Canda E; Kalkan Ucar S; Coker M
J Pediatr Endocrinol Metab; 2023 Jun; 36(6):530-538. PubMed ID: 37042760
[TBL] [Abstract][Full Text] [Related]
18. MAN1B-CDG: Novel variants with a distinct phenotype and review of literature.
Balasubramanian M; Johnson DS;
Eur J Med Genet; 2019 Feb; 62(2):109-114. PubMed ID: 29908352
[TBL] [Abstract][Full Text] [Related]
19. Type 2 diabetes mellitus facilitates endometrial hyperplasia progression by activating the proliferative function of mucin O-glycosylating enzyme GALNT2.
Zhou X; Xu Y; Yin D; Zhao F; Hao Z; Zhong Y; Zhang J; Zhang B; Yin X
Biomed Pharmacother; 2020 Nov; 131():110764. PubMed ID: 33152927
[TBL] [Abstract][Full Text] [Related]
20. Bi-allelic variants in the ER quality-control mannosidase gene EDEM3 cause a congenital disorder of glycosylation.
Polla DL; Edmondson AC; Duvet S; March ME; Sousa AB; Lehman A; ; Niyazov D; van Dijk F; Demirdas S; van Slegtenhorst MA; Kievit AJA; Schulz C; Armstrong L; Bi X; Rader DJ; Izumi K; Zackai EH; de Franco E; Jorge P; Huffels SC; Hommersom M; Ellard S; Lefeber DJ; Santani A; Hand NJ; van Bokhoven H; He M; de Brouwer APM
Am J Hum Genet; 2021 Jul; 108(7):1342-1349. PubMed ID: 34143952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
